Monoclonal antibody infliximab is used in treatment of Crohn’s disease. Crohn’s disease is a bowel diseases that results into inflammation of the digestive system resulting into abdominal pains.
ColoPulse drug delivery is an efficient and acceptable method of use in pediatric patients. This is as a result of maintaining efficacy, safety and accessibility (Lopez et al., 2015). Therefore, technology used in developing ColoPulse infliximab tablets comes with these advantages.
ColoPulse tablets are very promising when it comes to delivery of drugs to a certain specific site. A drug can be delivered into ileo-colonic region of the intestine for a patient suffering from Crohn’s disease. I understand that it is released once the pH of 7.0 is achieved which occurs in ileo-colonic region (Maurer et al., 2015). Therefore, it cannot be used for ailments in other regions as you have suggested.
References
Lopez, F. L., Ernest, T. B., Tuleu, C., & Gul, M. O. (2015). Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opinion on Drug Delivery, 12(11), 1727-1740. doi:10.1517/17425247.2015.1060218
Maurer, J. M., Schellekens, R. C., Van Rieke, H. M., Wanke, C., Iordanov, V., Stellaard, F., … Kosterink, J. G. (2015). Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. PLOS ONE, 10(7), e0129076. doi:10.1371/journal.pone.0129
PLACE THIS ORDER OR A SIMILAR ORDER WITH NURSING TERM PAPERS TODAY AND GET AN AMAZING DISCOUNT
